Expression of PPARγ and PTEN in human colorectal cancer: An immunohistochemical study using tissue microarray methodology

Oncology Letters

Volumn 2, Issue 6, 2011, Pages 1219-1224

  Lin, Mao Song ^a   Huang, Jun Xing ^a   Chen, Wei Chang ^b   Zhang, Bao Feng ^c   Fang, Jing ^c   Zhou, Qiong ^c   Hu, Ying ^c   Gao, Heng Jun ^c,d  

^a TAIZHOU PEOPLE S HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c NATIONAL ENGINEERING CENTER FOR BIOCHIP AT SHANGHAI   (China)

^d TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

Colorectal cancer; Immunohistochemistry; Peroxisome proliferator receptor ; Phosphatase and tensin homolog; Tissue microarray

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADENOMATOUS POLYP; ADULT; ARTICLE; CANCER INVASION; COLORECTAL CANCER; DIAGNOSTIC VALUE; DISTANT METASTASIS; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 80052740350     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.414     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer Statistics 2009. CA Cancer J Clin 59: 1-25, 2009.
2. Hung KE and Chung DC: New insights into the molecular pathogenesis of colorectal cancer. Drug Discov Today Dis Mech 3: 439-445, 2006.
3. Glass CK and Rosenfeld MG: The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14: 121-141, 2000.
4. Kliewer SA, Sundseth SS, Jones SA. Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM and Lehmann JM: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. PNAS 94: 4318-4323, 1997.
5. Matthiessen MW, Pedersen G, Albrektsen T, Adamsen S, Fleckner J and Brynskov J: Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand J Gastroenterol 40: 198-205, 2005.
6. Su WD, Bush CR, Necela BM, Calcagno SR, Murray NR, Fields AP and Thompson EA: Differential expression, distribution, and function of PPARγ in the proximal and distal colon. Physiol Genomics 30: 342-353, 2007.
7. Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schröder O and Stein J: PPARγ is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis 29: 1407-1414, 2008.
8. Eng C: PTEN: one gene, many syndromes. Hum Mutat 22: 183-198, 2003.
9. Nassif NT, Lobo GP, Wu X, Henderson CJ, Morrison CD, Eng C, Jalaludin B and Segelov E: PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene 23: 617-628, 2004.
10. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J and Pandolfi PP: The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 455: 813-817, 2008.
11. Lobo GP, Waite KA, Planchon SM, Romigh T, Nassif NT and Eng C: Germline and somatic cancer-associated mutations in the ATP-binding motifs of PTEN influence its subcellular localization and tumor suppressive function. Hum Mol Genet 18: 2851-2862, 2009.
12. Rahman MA, Dhar DK, Yamagicgi E, Maruyama S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H and Nagasue N: Coexpression of inducible nitric oxide synthase and COX-2in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 7: 1325-1332, 2001.
13. Nagata D, Yoshihiro H, Nakanishi M, Naruyama H, Okada S, Ando R, Tozawa K and Kohri K: Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer. Cancer Detect Prev 32: 259-66, 2008.
14. Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, Okuyama T, Rumi MA, Fukuda R, Nagasue N and Kinoshita Y: Expression of peroxisome proliferator-activated receptor (PPAR) γ in gastric cancer and inhibitory effects of PPARγ agonists. Br J Cancer 83: 1394-1400, 2000.
15. Sun WH, Chen GS, Ou XL, Yang Y, Luo C, Zhang Y, Shao Y, Xu HC, Xiao B, Xue YP, et al: Inhibition of COX-2and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells. Cancer Lett 275: 247-255, 2009.
16. Chen D, Jin GF, Wang Y, Wang H, Liu H, Liu Y, Fan W, Ma H, Miao R, Hu Z, et al: Genetic variants in peroxisome proliferator-activated receptor-γ gene are associated with risk of lung cancer in a Chinese population. Carcinogenesis 29: 342-350, 2008.
17. Mansen A, Guardiola-Diaz H, Rafter J, Branting C and Gustafsson JA: Expression of the peroxisome proliferators-activated receptor (PPAR) in the mouce colonic mucosa. Biochem Biophys Res Commun 222: 844-851, 1996.
18. Fujisawa T, Nakajima A, Fujisawa N, Takahashi H, Ikeda I, Tomimoto A, Yonemitsu K, Nakajima N, Kudo C, Wada K, et al: Peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses colonic epithelial cell turnover and colon carcinogenesis through inhibition of the beta-catenin/Tcell factor (TCF) pathway. J Pharmacol Sci 106: 627-38, 2008.
19. Eun CS, Han DS, Lee SH, Paik CH, Chung YW, Lee J and Hahm JS: Attenuation of colonic inflammation by PPARγ in intestinal epithelial cells: effect on toll-like receptor pathway. Dig Dis Sci 51: 693-697, 2006.
20. Feilchenfeldt J, Brundler MA, Soravia C, Totsch M and Meier CA: Peroxisome proliferators-activated receptors (PPARs) and associated transcription factors in colon cancer: reduced expression of PPARgamma-coactivator 1(PGC-1). Cancer Lett 203: 25-33, 2004.
21. Hisatake J, Ikezoe T, Carey M, Holden S, Tomoyasu S, and Koeffler HP: Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma (troglitazone) in human prostate cancer. Cancer Res 19: 5494-5498, 2000.
22. Puzio-Kuter AM, Martin MC, Kinkade CW, Wang X, Shen TH, Matos T, Shen MM, Cordon-Cardo C and Abate-Shen C: Inactivation of p53and Pten promotes invasive bladder cancer. Genes and Dev 23: 675-680, 2009.
23. Iwanaga K, Yang YN, Raso MG, Ma L, Hanna AE, Thilaganathan N, Moghaddam S, Evans CM, Li H, Cai WW, et al: Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res 68: 1119-1127, 2008.
24. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, et al: PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27: 2622-2629, 2009.
25. Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomaki P, De la Chapelle A, Aaltonen LA and Eng C: PTEN mutational spectra expression levels and subcellular localization in microsatellite stableand unstablecolorectal cancers. Am J Pathol 161: 439-447, 2002.
26. Lobo GP, Waite KA, Planchon SM, Romigh T, Houghton JA and Eng C: ATP modulates PTEN subcellular localization in multiple cancer cell lines. Hum Mol Genet 17: 2877-2885, 2008.
27. Bowen KA, Doan HQ, Zhou BP, Wang Q, Zhu Y, Rychahou PG and Evers BM: PTEN loss induces epithelial-mesenchymal transition in human colon cancer cells. Anticancer Res 29: 4439-4449, 2009.
28. Rychahou PG, Kang JH, Gulhati P, Doan HQ, Chen LA, Xiao SY, Chung DH, and Evers BM: Akt2over expression plays a critical role in the establishment of colorectal cancer metastasis. PNAS 105: 20315-20320, 2008.